[Updated on Apr. 18] Integration of CiNii Articles into CiNii Research

A case of MALT lymphoma coexisting with diffuse large B-cell lymphoma arising in the submaxillary gland

DOI Web Site 2 References Open Access
  • ICHIMURA Norihisa
    Department of Oral and Maxillofacial Surgery, Nagoya University Graduate School of Medicine
  • YAMAMOTO Noriyuki
    Department of Oral and Maxillofacial Surgery, Nagoya University Graduate School of Medicine
  • NISHIKAWA Masaya
    Department of Oral and Maxillofacial Surgery, Nagoya University Graduate School of Medicine
  • YAMAGUCHI Satoshi
    Department of Oral and Maxillofacial Surgery, Nagoya University Graduate School of Medicine
  • KANO Fumiya
    Department of Oral and Maxillofacial Surgery, Nagoya University Graduate School of Medicine
  • HIBI Hideharu
    Department of Oral and Maxillofacial Surgery, Nagoya University Graduate School of Medicine

Bibliographic Information

Other Title
  • 顎下腺に発生したびまん性大細胞型B細胞リンパ腫を含むMALTリンパ腫の1例
  • ガクカセン ニ ハッセイ シタ ビマンセイ ダイ サイボウガタ B サイボウ リンパシュ オ フクム MALT リンパシュ ノ 1レイ

Search this article

Abstract

<p>Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue type, referred to as mucosa-associated lymphoid tissue (MALT) lymphoma, arises as a low-grade B cell lymphoma associated with chronic inflammation. This disease is relatively rare and accounts for 0.3 percent of all malignant lymphomas. In this article, we report a case of MALT lymphoma coexisting with diffuse large B-cell lymphoma (DLBCL) arising in the submaxillary gland along with a literature review. A 67-year-old woman was referred to our hospital because of indolent right submandibular swelling. Palpable 30 × 25 mm mass was observed on the right submandible. Computed tomography (CT) showed a well-defined oval radiopaque mass measuring approximately 30 × 30 mm. We performed submaxillary gland resection with the patient under anesthesia for a suspected submaxillary gland tumor. A diagnosis of MALT lymphoma coexisting with DLBCL was made on the basis of the histopathological examination and immunohistochemical staining. As additional treatment, 3 cycles of rituximab with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) (R-CHOP) therapy were given after radiotherapy (36 Gy/20 fr) in accordance with the NCCN Guidelines. Currently, the patient is doing well with no recurrence.</p>

Journal

Citations (0)*help

See more

References(2)*help

See more

Related Articles

See more

Related Data

See more

Related Books

See more

Related Dissertations

See more

Related Projects

See more

Related Products

See more

Details

Report a problem

Back to top